4014: A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment OutcomesIn Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)

Project: Research project

Project Details

Description

4014: A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)
StatusActive
Effective start/end date1/1/1812/31/21

Funding

  • TAKEDA DEVELOPMENT CENTER AMERICAS, INC.

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.